Bioidentical hormones vs standard HRT: what is the difference?

Short answer

• “Bioidentical” means the hormone molecule is chemically identical to the hormone made in the human body (most commonly estradiol, progesterone, testosterone).
• “Standard” HRT usually refers to FDA‑approved hormone products that may be bioidentical (micronized estradiol or progesterone) or non‑bioidentical (conjugated equine estrogens, synthetic progestins). The key differences are the formulation, regulation, and evidence base — not an inherent safety advantage of the word “bioidentical.”

Definitions and how they differ

• Bioidentical hormone therapy (BHT/BHRT): uses hormones with the same molecular structure as human hormones (e.g., estradiol, micronized progesterone). BHRT can be prescribed as FDA‑approved products or as customized compounded preparations from a compounding pharmacy.
• Standard HRT: usually means FDA‑approved hormone products used to treat menopausal symptoms; some are bioidentical (oral or transdermal estradiol, micronized progesterone) and some are not (conjugated equine estrogens, synthetic progestins).

Important practical differences

• Regulation and consistency: FDA‑approved products (standard HRT) are manufactured to strict quality, potency, purity and labeling standards. Compounded BHRT is not FDA‑approved, can vary batch‑to‑batch, and has less oversight.
• Evidence: Most safety and effectiveness data come from FDA‑approved products. Compounded preparations have far less rigorous clinical trial evidence.
• Dosing and customization: Compounded BHRT is marketed as individually tailored (different doses, combinations, routes), which some patients and clinicians find helpful for symptom control — but “custom” does not guarantee better outcomes or safety.
• Route matters: Transdermal estradiol (patch, gel) appears to have lower risk of blood clots than oral estrogen. Progesterone (micronized) may have a different safety profile than synthetic progestins in some studies.

Examples (brands and what they are)

• FDA‑approved bioidentical products:
  • Climara, Vivelle‑Dot, Estraderm (estradiol patches) — stable transdermal delivery, associated with lower VTE risk than oral estrogen.
  • Estrace (oral estradiol) — oral estradiol tablets.
  • Prometrium (micronized progesterone) — bioidentical progesterone in capsule form, studied in trials and FDA‑approved.
• FDA‑approved non‑bioidentical examples (standard HRT):
  • Premarin (conjugated equine estrogens) — derived from horses, not biologically identical to human estradiol.
  • Provera (medroxyprogesterone acetate) — a synthetic progestin.
• Compounded BHRT:
  • Custom creams, troches, gels or mixes made by compounding pharmacies (e.g., Wedgewood Pharmacy, Empower Pharmacy — widely used compounding pharmacies). These are used when a clinician wants an individualized dose/combination, but they are not FDA‑approved and vary in oversight.

Safety and effectiveness — what the evidence says

• “Bioidentical” does not automatically mean safer. The risks associated with estrogen and progestogen (breast cancer, stroke, venous thromboembolism, cardiovascular disease) depend on type of hormone, dose, route, duration, and patient factors (age, time since menopause, personal/family history).
• Transdermal estradiol tends to have lower VTE risk vs oral estrogen. Micronized progesterone may have a more favorable profile for some outcomes vs synthetic progestins, but data are not definitive.
• Because compounded products lack large trials, their long‑term safety and efficacy are less well known.

Practical guidance

• Use evidence‑based, FDA‑approved products when possible — they offer consistent dosing, known safety profiles, and insurance coverage. Examples to discuss with your clinician: Vivelle‑Dot or Climara (estradiol patches) and Prometrium (micronized progesterone), if appropriate.
• Consider compounded BHRT only when a clear clinical reason exists (allergy to an excipient, need for a dose or combination not commercially available) and use a reputable, accredited compounding pharmacy. Ask about quality checks, certificates of analysis, and sterility testing.
• Route matters: if clot risk is a concern (history of VTE, obesity, smoking), discuss transdermal estradiol rather than oral.
• Talk to a clinician experienced in menopause care (ob/gyn, reproductive endocrinologist, or menopause specialist). Reputable centers include Mayo Clinic or Cleveland Clinic for evidence‑based evaluation; you can also consult resources from the North American Menopause Society (NAMS).

When to seek specialist input

• Persistent moderate–severe menopausal symptoms, complicated medical history (breast cancer, VTE, clotting disorders, cardiovascular disease), or interest in customized compounded preparations.

Quick summary

• Bioidentical refers to molecular structure; “standard” HRT refers to FDA‑approved hormone therapies (some bioidentical, some not).
• FDA‑approved bioidentical products (e.g., Vivelle‑Dot, Climara, Prometrium) are typically safer choices because they’re standardized and have better evidence. Compounded BHRT offers customization but has less regulation and less proven long‑term safety.
• Decide with a clinician using your health history, symptom severity, and preferences.

If you want, tell me your age, symptoms, medical history (especially clotting, breast cancer, heart disease), and whether you prefer oral, patch, or topical, and I can outline options and questions to ask a prescriber.